Clearmind Medicine Announces Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar
Clearmind Medicine (Nasdaq: CMND) announced the publication of an international patent application for a novel combination therapy targeting obesity and metabolic syndrome. The patent, filed under the Patent Cooperation Treaty (PCT), covers the combination of Clearmind's MEAI compound with SciSparc's PEA compound.
The therapy aims to address metabolic syndrome, which affects up to one-third of U.S. adults, combining MEAI's pharmacological profile with PEA's anti-inflammatory and neuroprotective properties. This development is part of a broader collaboration between Clearmind and SciSparc that has generated 13 patent families across multiple jurisdictions including the United States, Europe, and China.
Clearmind Medicine (Nasdaq: CMND) ha annunciato la pubblicazione di una domanda di brevetto internazionale per una nuova terapia combinata rivolta all'obesit脿 e alla sindrome metabolica. Il brevetto, depositato ai sensi del Trattato di Cooperazione in materia di Brevetti (PCT), riguarda la combinazione del composto MEAI di Clearmind con il composto PEA di SciSparc.
La terapia mira a contrastare la sindrome metabolica, che colpisce fino a un terzo degli adulti negli Stati Uniti, unendo il profilo farmacologico di MEAI alle propriet脿 antinfiammatorie e neuroprotettive di PEA. Questo sviluppo fa parte di una pi霉 ampia collaborazione tra Clearmind e SciSparc che ha prodotto 13 famiglie di brevetti in diverse giurisdizioni, tra cui Stati Uniti, Europa e Cina.
Clearmind Medicine (Nasdaq: CMND) anunci贸 la publicaci贸n de una solicitud de patente internacional para una novedosa terapia combinada dirigida a la obesidad y el s铆ndrome metab贸lico. La patente, presentada bajo el Tratado de Cooperaci贸n en materia de Patentes (PCT), cubre la combinaci贸n del compuesto MEAI de Clearmind con el compuesto PEA de SciSparc.
La terapia busca tratar el s铆ndrome metab贸lico, que afecta a hasta un tercio de los adultos en EE. UU., combinando el perfil farmacol贸gico de MEAI con las propiedades antiinflamatorias y neuroprotectoras de PEA. Este avance forma parte de una colaboraci贸n m谩s amplia entre Clearmind y SciSparc que ha generado 13 familias de patentes en m煤ltiples jurisdicciones, incluyendo Estados Unidos, Europa y China.
Clearmind Medicine (雮橃姢雼�: CMND)電� 牍勲 氚� 雽�靷� 歃濏泟甑办潉 瓴儱頃� 靸堧鞖� 氤戩毄 鞖旊矔鞐� 雽�頃� 甑牅 韸鬼棃 於滌洂鞚� 氚滍憸頄堨姷雼堧嫟. 鞚� 韸鬼棃電� 韸鬼棃 順戨牓 臁办暯(PCT)鞐� 霐半澕 於滌洂霅橃棃鞙茧┌, Clearmind鞚� MEAI 頇旐暕氍缄臣 SciSparc鞚� PEA 頇旐暕氍检潣 臁绊暕鞚� 韽暔頃╇媹雼�.
鞚� 旃橂氩曥潃 氙戈淡 靹膘澑鞚� 斓滊寑 3攵勳潣 1鞐� 鞓來枼鞚� 氙胳箻電� 雽�靷� 歃濏泟甑办潉 雽�靸侅溂搿� 頃橂┌, MEAI鞚� 鞎诫Μ頃欖爜 韸轨劚瓿� PEA鞚� 頃椉 氚� 鞁犼步 氤错樃 韸轨劚鞚� 瓴绊暕頃╇媹雼�. 鞚� 臧滊皽鞚� Clearmind鞕� SciSparc 臧勳潣 甏戨矓鞙勴暅 順戨牓鞚� 鞚柬櫂鞙茧, 氙戈淡, 鞙犽熃, 欷戧淡 霌� 鞐煬 甏�頃� 甑棴鞐愳劀 13臧滌潣 韸鬼棃 韺皜毽�毳� 於滌洂頃� 氚� 鞛堨姷雼堧嫟.
Clearmind Medicine (Nasdaq : CMND) a annonc茅 la publication d'une demande de brevet internationale pour une nouvelle th茅rapie combin茅e ciblant l'ob茅sit茅 et le syndrome m茅tabolique. Le brevet, d茅pos茅 dans le cadre du Trait茅 de coop茅ration en mati猫re de brevets (PCT), couvre la combinaison du compos茅 MEAI de Clearmind avec le compos茅 PEA de SciSparc.
Cette th茅rapie vise 脿 traiter le syndrome m茅tabolique, qui touche jusqu'脿 un tiers des adultes aux 脡tats-Unis, en associant le profil pharmacologique du MEAI aux propri茅t茅s anti-inflammatoires et neuroprotectrices du PEA. Ce d茅veloppement s'inscrit dans une collaboration plus large entre Clearmind et SciSparc qui a g茅n茅r茅 13 familles de brevets dans plusieurs juridictions, notamment aux 脡tats-Unis, en Europe et en Chine.
Clearmind Medicine (Nasdaq: CMND) gab die Ver枚ffentlichung einer internationalen Patentanmeldung f眉r eine neuartige Kombinationstherapie zur Behandlung von Adipositas und metabolischem Syndrom bekannt. Das unter dem Patentzusammenarbeitsvertrag (PCT) eingereichte Patent umfasst die Kombination der MEAI-Verbindung von Clearmind mit der PEA-Verbindung von SciSparc.
Die Therapie zielt darauf ab, das metabolische Syndrom zu behandeln, das bis zu einem Drittel der erwachsenen US-Bev枚lkerung betrifft, indem das pharmakologische Profil von MEAI mit den entz眉ndungshemmenden und neuroprotektiven Eigenschaften von PEA kombiniert wird. Diese Entwicklung ist Teil einer umfangreicheren Zusammenarbeit zwischen Clearmind und SciSparc, die 13 Patentfamilien in mehreren Rechtsgebieten, darunter die USA, Europa und China, hervorgebracht hat.
- Publication of international patent application strengthens intellectual property portfolio
- Collaboration has resulted in 13 patent families across major jurisdictions
- Targets large market opportunity with metabolic syndrome affecting one-third of U.S. adults
- Novel combination therapy leverages complementary properties of both compounds
- Early-stage development with no clinical efficacy data presented
- Patent application publication does not guarantee patent approval
Insights
Clearmind's PCT patent filing for MEAI-PEA combination therapy strengthens IP position but remains early-stage with no clinical validation yet.
Clearmind Medicine has published an international PCT patent application covering a combination therapy of their proprietary compound MEAI with SciSparc's PEA, targeting metabolic syndrome and obesity. This strategic IP move expands their portfolio to 13 patent families across major markets including the US, Europe, and China.
The patent specifically addresses metabolic syndrome - a condition affecting up to one-third of US adults characterized by high blood pressure, elevated blood sugar, excess abdominal fat, and abnormal cholesterol levels. This represents a massive potential market with significant unmet medical needs.
What's noteworthy about this approach is the combination mechanism - MEAI's psychedelic-derived pharmacological profile complemented by PEA's anti-inflammatory and neuroprotective properties. This dual-action strategy may offer advantages over single-compound approaches to these complex metabolic disorders.
However, investors should understand that this is an early-stage intellectual property filing with no mention of clinical validation. PCT publication is merely a procedural step in the international patent process, not regulatory approval or clinical validation. The press release contains no data on efficacy, safety, or timelines for potential commercialization.
While the collaboration with SciSparc demonstrates business development activity and the potential to share development costs, no financial terms are disclosed. The company appears to be building a defensive IP position around its core MEAI compound by filing multiple patent families across different therapeutic applications, potentially creating optionality for future development or partnership opportunities.
Vancouver, Canada, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (鈥淐learmind鈥� or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the publication of an international patent application under the Patent Cooperation Treaty (PCT) as part of its ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC) ("SciSparc"), a specialty clinical-stage pharmaceutical company developing therapies for central nervous system disorders.
The patent application published under the European Patent Office covers an innovative combination therapy of Clearmind鈥檚 proprietary 5-methoxy-2-aminoindane (MEAI) and SciSparc鈥檚 Palmitoylethanolamide (PEA) for the treatment of metabolic syndrome and obesity.
Metabolic syndrome, characterized by conditions such as high blood pressure, high blood sugar, excess abdominal fat, and elevated cholesterol levels, affects up to one-third of U.S. adults and increases the risk of heart disease, stroke, obesity and type 2 diabetes. This proprietary combination therapy leverages MEAI鈥檚 unique pharmacological profile alongside PEA鈥檚 anti-inflammatory and neuroprotective properties to offer a potential safe and effective treatment for these widespread health challenges.
This patent publication marks a significant milestone in the Clearmind-SciSparc collaboration, which has resulted in the filing of 13 patent families, across multiple jurisdictions, such as the United States, Europe, and China. The collaboration focuses on developing innovative therapies that combine neuroplastogens molecules with N-acylethanolamines, including PEA, to address mental health disorders such as depression and PTSD, addictions, and various metabolic conditions and obesity.
Dr. Adi Zuloff-Shani, CEO of Clearmind, stated: 鈥淲e continue our strategy to develop breakthrough therapies to treat complex health conditions, with our intellectual property portfolio enabling us to potentially redefine therapeutic approaches for metabolic syndrome and obesity, leveraging, among others, the synergistic effects of MEAI and PEA.鈥�
About聽Clearmind聽Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company鈥檚 intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol 鈥淐WY0.鈥�
For further information visit:聽聽or contact:
Investor Relations
Telephone: (604) 260-1566
鲍厂:听
General Inquiries
Forward-Looking Statements:
This press release contains 鈥渇orward-looking statements鈥� within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as 鈥渆xpects,鈥� 鈥渁nticipates,鈥� 鈥渋ntends,鈥� 鈥減lans,鈥� 鈥渂elieves,鈥� 鈥渟eeks,鈥� 鈥渆stimates鈥� and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses聽its strategy to develop breakthrough therapies to treat complex health conditions and how its intellectual property portfolio enables it to potentially redefine therapeutic approaches for metabolic syndrome and obesity, leveraging, among others, the synergistic effects of MEAI and PEA .聽 The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management鈥檚 current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith.聽However, there can be no assurance that management鈥檚 expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is聽made to the Company鈥檚 reports filed from time to time with the Securities and Exchange Commission (鈥淪EC鈥�), including, but not limited to, the risks detailed in the Company鈥檚 annual report on Form 20-F for the fiscal year ended October 31,聽2024聽and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What is the new patent application from Clearmind Medicine (CMND) about?
How many patent families has the Clearmind-SciSparc collaboration generated?
What medical conditions does Clearmind's new combination therapy target?
What is the market potential for Clearmind's metabolic syndrome treatment?
What compounds are used in Clearmind's new combination therapy?
